文献速递骨质疏松与代谢性骨病创伤骨科

全身性糖皮质激素使用在伴与不伴2型糖尿病人群中增加骨折风险程度相似:丹麦全国队列研究

Systemic glucocorticoid use increases fracture risk similarly in individuals with and without type 2 diabetes: a Danish nationwide cohort study.
PubMed 文献 · Osteoporos Int · 2026-09-11

该丹麦全国注册队列研究纳入477,605例使用全身性糖皮质激素的个体(27,942例伴2型糖尿病),采用自身治疗前对照期和标准化发病比加权,发现糖皮质激素治疗与主要骨质疏松性骨折风险增加相关(IRR 1.70 [1.55-1.85]),且2型糖尿病状态未显著改变该效应(乘积项IRR 1.01 [0.87-1.17])。

要点

  • 全身性糖皮质激素使用使主要骨质疏松性骨折风险增加约70%。
  • 2型糖尿病状态未显著改变糖皮质激素对骨折风险的影响。
  • 对已骨折风险增高的2型糖尿病患者处方糖皮质激素需谨慎。

核心结论

  • 全身性糖皮质激素使用在伴与不伴2型糖尿病的个体中增加骨折风险的程度相似。
  • 未观察到2型糖尿病对糖皮质激素致骨折风险有增效作用。

研究设计与样本

  • 丹麦全国注册队列研究,采用个体内治疗前参考期设计。
  • 纳入2000至2018年间接受全身性糖皮质激素治疗(≥1次取药处方)的个体,共477,605例(27,942例伴2型糖尿病),总随访1,358,739人年。
  • 使用标准化发病比(SMR)加权控制混杂,采用零膨胀负二项模型估计发病率比(IRR)。

主要发现

  • 共观察21,581例主要骨质疏松性骨折(髋、椎体、肱骨或前臂骨折)。
  • 糖皮质激素治疗期间中位随访35天(均值212天),治疗前参考期中位随访731天。
  • 加权后,糖皮质激素治疗与主要骨质疏松性骨折风险的IRR为1.70 [1.55-1.85]。
  • 2型糖尿病对糖皮质激素效应的修饰作用无统计学证据,乘积项IRR为1.01 [0.87-1.17]。
  • 按性别、年龄(<65岁、65-74岁、≥75岁)分层及多种敏感性分析结果相似。

临床怎么用

  • 对2型糖尿病患者处方全身性糖皮质激素时,应认识到其骨折风险已因糖尿病而增高,糖皮质激素会进一步增加风险。
  • 无需因2型糖尿病状态而改变对糖皮质激素相关骨折风险的评估,但应加强骨折风险监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Type 2 diabetes (T2D) and glucocorticoid treatment both increase risk of bone fractures. We found that glucocorticoid use increases fracture risk similarly regardless of T2D status. Findings were consistent over time and across subgroups. Care should be taken when prescribing glucocorticoids to individuals with T2D already at increased fracture risk. BACKGROUND: Type 2 diabetes (T2D) is associated with increased risk of bone fractures, which may be caused by suppressed bone formation. Similarly, glucocorticoid (GC) treatment leads to suppressed bone formation, in addition to increased resorption. It is unknown whether GC treatment alters fracture risk equally in subjects with and subjects without T2D. METHODS: We performed a nationwide registry-based cohort study with a within-subject pre-treatment reference period to investigate whether T2D status modified the effects of systemic GCs on risk of first major osteoporotic fractures (MOFs)-defined as fractures of the hips, vertebrae, humerus, or forearm-within each observation period. Individuals with or without T2D receiving systemic GC treatment (≥ 1 redeemed prescription) between 2000 and 2018 were identified and followed during treatment. The reference period for GC treatment consisted of the 2-year period immediately prior to treatment in any given individual. For confounding control, we used standardized morbidity ratio (SMR) weighting. Each group (with/without T2D and during/before GC) was reweighted to resemble the T2D group in the GC treatment period. Incidence rate ratios (IRR) were estimated using a zero-inflated negative binomial model with predictors being T2D, GC treatment, and a product term between the two. A product term estimate > 1 represents a larger effect of GC among the T2D group than in the non-T2D group. RESULTS: We included 477,605 individuals (27,942 with T2D) with a total follow-up time of 1,358,739 person-years. A total of 21,581 MOFs were observed. Median follow-up time was 35 days (with a mean of 212 days) during GC treatment and 731 days in the pre-treatment period. After weighting, GC treatment was associated with an IRR of 1.70 [1.55-1.85], with no evidence of effect modification by T2D (product term IRR 1.01 [0.871.17]). These results were similar across subgroup and sensitivity analyses; when stratifying by sex (males vs. females) or age (< 65 years, 6574 years, and ≥ 75 years), when counting recurring fractures during treatment, when allowing the effects of GC treatment to vary smoothly as a function of time-since-initiation, when accounting for differences in daily dosage with different durations of treatment, and under alternative modeling specifications. CONCLUSION: We found that systemic GC use increases fracture risk to a similar degree in individuals with and individuals without T2D. While no potentiating effect was observed, individuals with T2D receiving GC treatment experience increased risk through multiple paths, and care should be taken when prescribing GCs in this population.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Al-Mashhadi ZK, Viggers R, Starup-Linde J, et al. Systemic glucocorticoid use increases fracture risk similarly in individuals with and without type 2 diabetes: a Danish nationwide cohort study. Osteoporos Int. 2026. PMID: 42722898. doi:10.1007/s00198-026-08206-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。